EA201991990A1 - Фармацевтические композиции для комбинированной терапии - Google Patents

Фармацевтические композиции для комбинированной терапии

Info

Publication number
EA201991990A1
EA201991990A1 EA201991990A EA201991990A EA201991990A1 EA 201991990 A1 EA201991990 A1 EA 201991990A1 EA 201991990 A EA201991990 A EA 201991990A EA 201991990 A EA201991990 A EA 201991990A EA 201991990 A1 EA201991990 A1 EA 201991990A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
combined therapy
combination
phenyl
cenicrivirok
Prior art date
Application number
EA201991990A
Other languages
English (en)
Inventor
Эмелин Декам
Роберт Вальчак
Кароль Беланже
Бенуа Ноэль
Original Assignee
Женфит
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Женфит filed Critical Женфит
Publication of EA201991990A1 publication Critical patent/EA201991990A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Настоящее изобретение относится к фармацевтической комбинации, содержащей агонист PPAR и (S,Е)-8-(4-(2-бутоксиэтокси)фенил)-1-(2-метилпропил)-N-(4-((((1-пропил)-1Н-имидазол-5-ил)метил)сульфинил)фенил)-1,2,3,4-тетрагидробензо[b]азоцин-5-карбоксамид, также известный как ценикривирок (CVC), или его производные, и её применению. Комбинация может быть полезна в комбинированной терапии для лечения воспалительных, метаболических, фиброзных и холестатических заболеваний.
EA201991990A 2017-02-24 2018-02-23 Фармацевтические композиции для комбинированной терапии EA201991990A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305213 2017-02-24
PCT/EP2018/054588 WO2018154081A1 (en) 2017-02-24 2018-02-23 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
EA201991990A1 true EA201991990A1 (ru) 2020-04-07

Family

ID=58231557

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991990A EA201991990A1 (ru) 2017-02-24 2018-02-23 Фармацевтические композиции для комбинированной терапии

Country Status (14)

Country Link
US (1) US11590108B2 (ru)
EP (1) EP3585384A1 (ru)
JP (1) JP2020510651A (ru)
KR (1) KR102633249B1 (ru)
CN (1) CN110418641A (ru)
AU (1) AU2018223976B2 (ru)
BR (1) BR112019017314A2 (ru)
CA (1) CA3051977A1 (ru)
EA (1) EA201991990A1 (ru)
IL (1) IL268708B (ru)
MX (1) MX2019009909A (ru)
PH (1) PH12019501820A1 (ru)
SG (1) SG11201907084VA (ru)
WO (1) WO2018154081A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102338085B1 (ko) * 2016-03-31 2021-12-10 장피트 담즙울체성 질환의 치료 방법
US20220133666A1 (en) * 2016-03-31 2022-05-05 Genfit Methods of treatment of cholestatic diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339340T3 (es) 2001-08-08 2010-05-19 Tobira Therapeutics, Inc. Compuesto biciclico, produccion y su uso.
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
EA020849B1 (ru) * 2009-11-26 2015-02-27 Женфит Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
SG10201909122QA (en) * 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SG10201808104RA (en) * 2014-03-21 2018-10-30 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
EP3777863A1 (en) * 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
EP3349751A4 (en) 2015-09-16 2019-05-22 Tobira Therapeutics, Inc. CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS
KR102338085B1 (ko) * 2016-03-31 2021-12-10 장피트 담즙울체성 질환의 치료 방법
AU2017249603B2 (en) 2016-04-11 2022-12-01 Genfit Methods of treatment for cholestatic and fibrotic diseases
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
SG11201906041QA (en) 2017-01-27 2019-08-27 Genfit Pharmaceutical compositions for combination therapy

Also Published As

Publication number Publication date
CN110418641A (zh) 2019-11-05
US11590108B2 (en) 2023-02-28
US20190388394A1 (en) 2019-12-26
AU2018223976A1 (en) 2019-09-05
IL268708A (en) 2019-10-31
CA3051977A1 (en) 2018-08-30
JP2020510651A (ja) 2020-04-09
KR102633249B1 (ko) 2024-02-02
KR20190119097A (ko) 2019-10-21
MX2019009909A (es) 2019-10-14
BR112019017314A2 (pt) 2020-04-14
SG11201907084VA (en) 2019-09-27
IL268708B (en) 2022-05-01
PH12019501820A1 (en) 2020-09-14
WO2018154081A1 (en) 2018-08-30
AU2018223976B2 (en) 2023-08-17
EP3585384A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
EA201792047A1 (ru) Новые соединения
EA201790202A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2015017964A (es) Inhibidores de bromodominio.
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
CY1125179T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεïνης ενεργοποιησης της 5-λιποξυγενασης (flap)
PH12016502353A1 (en) Pharmaceutical composition
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201991990A1 (ru) Фармацевтические композиции для комбинированной терапии